These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Bone marrow function during quadruple immunosuppressive therapy after renal transplantation.
    Author: Heaf J.
    Journal: Clin Nephrol; 1993 Dec; 40(6):332-8. PubMed ID: 8299241.
    Abstract:
    Bone marrow function was evaluated in 50 patients treated with quadruple immunotherapy (prednisone, azathioprine, anti-lymphocyte globulin [ALG] until creatinine clearance > 10 min, cyclosporine thereafter) after renal transplantation. Thrombocytopenia (< 100 mio./ml) developed in 30% of patients and leucopenia in 4%. Leucopenia was always accompanied by thrombocytopenia. Thrombocytopenia usually developed within 3 days of the operation. The most significant factors in the development of thrombocytopenia were ALG treatment and a low platelet count (< 250 mio./ml) on admission. The toxic effect of ALG was immediate, but disappeared within 5 days of ALG discontinuation. Other factors of importance were female sex, low weight (< 70 kg) and long (> 1 year) dialysis duration. Cyclosporine had no toxic effect. Azathioprine treatment played only a minor role in the development of thrombocytopenia but patients with low (100-200 mio./ml) and falling platelet counts who later developed thrombocytopenia were treated with significantly (p < 0.01) higher azathioprine dosages. The present study suggests that thrombocytopenia incidence can be reduced if azathioprine treatment is reduced to 1 mg/kg/day under the following circumstances: 1) small female patients; 2) platelet count < 250 mio./ml on admission; 3) platelet count < 200 during admission and falling. ALG treatment should usually be limited to 14 days, but azathioprine dosage can safely be increased after ALG discontinuation.
    [Abstract] [Full Text] [Related] [New Search]